Paxlovid, a five-day course of pills from Pfizer, is a highly recommended treatment for COVID-19. Despite the Biden administration's effort to make the medicines easy to obtain after a positive test for COVID-19, some still have issues obtaining it.
” below to learn about and use cookie management tools to limit use of cookies when you visit NPR’s sites.
This page will also tell you how you can reject cookies and still obtain access to NPR’s sites, and you can adjust your cookie choices in those tools at any time. If you click “” below, you acknowledge that your cookie choices in those tools will be respected and that you otherwise agree to the use of cookies on NPR’s sites.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Covid-19 news: Easing zero-covid may cause 1.5 million deaths in ChinaToday’s covid-19 news: · Ending China’s zero-covid policy could cause 1.5 million deaths · Vaccinated pregnant people are 15 per cent less likely to have a stillbirth than their unvaccinated counterparts · New Zealand passes 1 million reported cases
Read more »
3 Ways To Get COVID-19 Pills, If You’ve Just Tested PositiveSome people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a test confirms infection.
Read more »
Chicago’s Top Doc on COVID-19 Increase and ‘Medium Risk’ DesignationDr. Allison Arwady joined “Chicago Tonight” to talk about what is driving the rising number of COVID cases in Chicago and the factors that may influence decisions around mask requirements.
Read more »
Several Marin Schools Experience COVID-19 Outbreaks: ReportSeveral Marin schools are experiencing COVID-19 outbreaks, according to a newspaper report, and officials are recommending students reconsider masks for certain indoor activities and events.
Read more »
Why Even A Less Effective COVID-19 Vaccine Is Worth GettingThe mRNA COVID-19 vaccines available in the United States work. But how well they work, by what metrics and for whom … that’s all unfortunately in flux. S…
Read more »